Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Postoperative Sleep Study in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Breast cancer patients having a unilateral segmental mastectomy, with or without intraoperative lymph node mapping, sentinel node biopsy, and axillary node dissection~2. Ages \>= 40 years~3. American Society of Anesthesiology (ASA) physical status classification of preoperative functioning) 1-4 levels are acceptable~4. Willing and able to give written informed consent~5. Willing and able to complete questionnaires~6. Not currently taking benzodiazepine medication for insomnia.~Exclusion Criteria:~1. Autoimmune diseases: rheumatoid arthritis, systemic lupus, or other collagen vascular disease~2. Alcoholics~3. Seizure disorder~4. Thyroid disease~5. Pregnant or lactating patients (effects not known in pregnancy)~6. Renal/hepatic failure (if ood urea nitrogen (BUN) or creatinine (Cr) \>2.5\* Upper limit of normal (ULN); Bili or aspartate aminotransferase (AST) or alanine aminotransferase (ALT)\>2.5\* ULN)~7. Dementia/poor compliance~8. Manic/psychotic patients~9. Children/adults under 40 yrs~10. Movement disorders (ex. restless leg syndrome)~11. Tremor disorder (ex. parkinsonism)~12. Chronic benzodiazepine use for sleep (\>4 times per week )~13. Designated preop medications including melatonin for sleep

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): 0.15 mg/kg capsules by mouth daily
- Placebo (Type: PLACEBO_COMPARATOR): Starch capsules by mouth daily

Based on this trial design, predict the completion outcome and termination type (if applicable).